Connect with us
  • Elysium


NICE backs AF detection device in NHS first



The National Institute for Health and Care Excellence (NICE) has backed AliveCor’s KardiaMobile device for personal at-home atrial fibrillation (AF) monitoring.

KardiaMobile is the only personal electrocardiogram (ECG) to be recommended by NICE for use within the NHS.

The guidance recommends the device an option for detecting AF for people with suspected paroxysmal AF, who present with symptoms such as palpitations and are referred for ambulatory ECG monitoring by a clinician.

The device would be prescribed to people experiencing arrhythmia symptoms more than 24 hours apart.

AF is a leading cause of stroke, with almost 1.3million people in the UK undiagnosed.

Mrs Trudie Lobban MBE, Founder and Trustee of Arrhythmia Alliance & AF Association, said:

“Many people experience various symptoms but do not realise it may be a heart rhythm disorder such as AF.

“If medical attention is not sought it leaves them exposed to a much higher risk of AF-related stroke.

“KardiaMobile can be used to monitor a person’s heart rhythm at any time, regardless of whether or not people show signs or symptoms of AF.

“This ultimately means AF can be detected faster, leading to a quicker diagnosis and therefore more lives being protected against AF-related stroke and consequences of suffering with AF.”

The user starts a 30-second ECG recording on their smartphone via the Kardia app by placing two fingers from each hand on each of the two top electrodes.

This enables the patient to remotely capture a medical-grade recording of their heart activity.

KardiaMobile provides instant detection of AF, bradycardia and tachycardia, which are leading indicators of cardiovascular disease.

AliveCor CEO, Priya Abani, said:

“AliveCor is proud to be able to offer the only NICE-recommended personal ECG to support remote cardiac care services for patients not in front of their cardiologist.

“Today’s recommendation not only highlights the clinical superiority of KardiaMobile against the current standard of care, but also its position as a more cost-effective solution, therefore warranting its value as a clinical tool to support rapid diagnosis of AF.”